- Home
- GMAB vs NVT Comparison
GMAB vs NVT Comparison
Compare GMAB & NVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- NVT
- Stock Information
- Founded
- GMAB 1999
- NVT 1903
- Country
- GMAB Denmark
- NVT United Kingdom
- Employees
- GMAB N/A
- NVT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- NVT Industrial Machinery/Components
- Sector
- GMAB Health Care
- NVT Industrials
- Exchange
- GMAB Nasdaq
- NVT Nasdaq
- Market Cap
- GMAB 17.4B
- NVT 18.1B
- IPO Year
- GMAB N/A
- NVT N/A
- Fundamental
- Price
- GMAB $30.42
- NVT $106.44
- Analyst Decision
- GMAB Strong Buy
- NVT Strong Buy
- Analyst Count
- GMAB 6
- NVT 11
- Target Price
- GMAB $40.40
- NVT $103.45
- AVG Volume (30 Days)
- GMAB 2.4M
- NVT 2.4M
- Earning Date
- GMAB 11-06-2025
- NVT 10-31-2025
- Dividend Yield
- GMAB N/A
- NVT 0.75%
- EPS Growth
- GMAB 132.41
- NVT 6.36
- EPS
- GMAB 25.10
- NVT 3.64
- Revenue
- GMAB $3,845,670,022.00
- NVT $3,578,600,000.00
- Revenue This Year
- GMAB $24.92
- NVT $27.44
- Revenue Next Year
- GMAB $15.97
- NVT $12.69
- P/E Ratio
- GMAB $11.82
- NVT $59.58
- Revenue Growth
- GMAB 29.57
- NVT 21.54
- 52 Week Low
- GMAB $17.24
- NVT $41.71
- 52 Week High
- GMAB $33.65
- NVT $117.52
- Technical
- Relative Strength Index (RSI)
- GMAB 56.40
- NVT 51.88
- Support Level
- GMAB $28.08
- NVT $109.51
- Resistance Level
- GMAB $30.78
- NVT $112.46
- Average True Range (ATR)
- GMAB 0.68
- NVT 4.24
- MACD
- GMAB 0.10
- NVT -0.57
- Stochastic Oscillator
- GMAB 84.63
- NVT 32.74
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.